{
    "organizations": [],
    "uuid": "9b61e47afdb57dab2e5ce985c2419544c98a1a88",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/biogen-study/biogen-stops-developing-tysabri-to-treat-stroke-after-failed-study-idUSL4N1PX4PT",
    "ord_in_thread": 0,
    "title": "Biogen stops developing Tysabri to treat stroke after failed study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 7 (Reuters) - Biogen Inc said on Wednesday it would stop developing Tysabri to treat acute ischemic stroke patients after the drug failed to meet the main goal of a mid-stage study.\nTysabri is already approved to treat multiple sclerosis. (Reporting by Manas Mishra in Bengaluru; Editing by Savio Dâ€˜Souza)\n ",
    "published": "2018-02-07T20:44:00.000+02:00",
    "crawled": "2018-02-09T06:10:43.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "biogen",
        "inc",
        "said",
        "wednesday",
        "would",
        "stop",
        "developing",
        "tysabri",
        "treat",
        "acute",
        "ischemic",
        "stroke",
        "patient",
        "drug",
        "failed",
        "meet",
        "main",
        "goal",
        "study",
        "tysabri",
        "already",
        "approved",
        "treat",
        "multiple",
        "sclerosis",
        "reporting",
        "manas",
        "mishra",
        "bengaluru",
        "editing",
        "savio",
        "souza"
    ]
}